Small Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive global coverage of pipeline NSCLC therapies in ...

GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will ...

Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating ...

H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Cogent Biosciences (COGT) to $14 from $17 and keeps a Buy rating on the ...

Ancestry-based differences in frequencies of biomarkers that drive patient selection for treatment with precision oncology ...

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...

Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS ® (savolitinib) has been granted approval by the China National Medical ...

Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS® (savolitinib) has been granted approval by the China National Medical Products ...

Johnson & Johnson, already a big player in neuroscience drugs, is adding to its portfolio and pipeline with a deal to acquire Intra-Cellular Therapies, a company whose main asset has the potential to ...

Prothena Biosciences Ltd. and Vanderbilt University have jointly discovered dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors reported to be useful for the treatment of ...

Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.

In a pooled analysis from two trials, Dato-DXd has shown promise as a treatment for advanced EGFR-mutated NSCLC.